Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies

Yuri M. Falzone, Marta Campagnolo, Mariangela Bianco, Patrizia Dacci, Daniele Martinelli, Marta Ruiz, Silvia Bocci, Federica Cerri, Angelo Quattrini, Giancarlo Comi, Luana Benedetti, Fabio Giannini, Giuseppe Lauria, Eduardo Nobile-Orazio, Chiara Briani, Raffaella Fazio, Nilo Riva

Research output: Contribution to journalArticle

Abstract

Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients.
Original languageEnglish
JournalJournal of Neurology
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Myelin-Associated Glycoprotein
Fatigue
Quality of Life
Antibodies
Biomedical Research
International Classification of Functioning, Disability and Health
Social Participation
Pain Measurement
Pain Management
Visual Analog Scale
Health Status
Walking
Cross-Sectional Studies
Outcome Assessment (Health Care)
Clinical Trials

Keywords

  • Balance
  • Chronic inflammatory polyneuropathy
  • MGUS
  • Pain
  • Rehabilitation
  • Walking ability

Cite this

Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies. / Falzone, Yuri M.; Campagnolo, Marta; Bianco, Mariangela; Dacci, Patrizia; Martinelli, Daniele; Ruiz, Marta; Bocci, Silvia; Cerri, Federica; Quattrini, Angelo; Comi, Giancarlo; Benedetti, Luana; Giannini, Fabio; Lauria, Giuseppe; Nobile-Orazio, Eduardo; Briani, Chiara; Fazio, Raffaella; Riva, Nilo.

In: Journal of Neurology, 01.01.2018.

Research output: Contribution to journalArticle

@article{21cba3d8368f404bb335d5958de6d2ec,
title = "Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies",
abstract = "Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52{\%} of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41{\%} of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54{\%} of its variance. FSS was the most reliable determinant of MCS, explaining 25{\%} of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients.",
keywords = "Balance, Chronic inflammatory polyneuropathy, MGUS, Pain, Rehabilitation, Walking ability",
author = "Falzone, {Yuri M.} and Marta Campagnolo and Mariangela Bianco and Patrizia Dacci and Daniele Martinelli and Marta Ruiz and Silvia Bocci and Federica Cerri and Angelo Quattrini and Giancarlo Comi and Luana Benedetti and Fabio Giannini and Giuseppe Lauria and Eduardo Nobile-Orazio and Chiara Briani and Raffaella Fazio and Nilo Riva",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00415-018-9081-7",
language = "English",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies

AU - Falzone, Yuri M.

AU - Campagnolo, Marta

AU - Bianco, Mariangela

AU - Dacci, Patrizia

AU - Martinelli, Daniele

AU - Ruiz, Marta

AU - Bocci, Silvia

AU - Cerri, Federica

AU - Quattrini, Angelo

AU - Comi, Giancarlo

AU - Benedetti, Luana

AU - Giannini, Fabio

AU - Lauria, Giuseppe

AU - Nobile-Orazio, Eduardo

AU - Briani, Chiara

AU - Fazio, Raffaella

AU - Riva, Nilo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients.

AB - Although anti-myelin-associated glycoprotein (MAG) antibody neuropathy is reported as a slowly progressive disease, it can lead to significant disability and impairment of health-related quality of life (HR-QoL) and social participation. The aim of this cross-sectional study was to evaluate the functioning and HR-QoL determinants in 67 patients with anti-MAG neuropathy in terms of the International Classification of Functioning, Disability, and Health (ICF). Evaluations included: Medical Research Council (MRC) sum score, Sensory Modality Sum score (SMS), Berg balance scale (BBS), Fatigue Severity Scale (FSS), Visual Analogue Scale (VAS) for pain, 9-Hole Peg Test (9-HPT), 6-min Walk Distance (6MWD), Impact on Participation and Autonomy (IPA) and the physical component score (PCS) and mental component score (MCS) of the short-form-36 health status scale (SF-36) HR-QoL measure. In the regression models, 6MWD was the most reliable predictor of PCS, explaining the 52% of its variance, while the strongest determinants of 6MWD were BBS and FSS, explaining the 41% of its variance. Consistently, VAS and BBS were good predictor of PCS, explaining together 54% of its variance. FSS was the most reliable determinant of MCS, explaining 25% of its variance. SMS and MRC were not QoL determinants. The results of our study suggest that 6MWD and FSS might be considered as potential meaningful outcome measures in future clinical trials. Furthermore, neurorehabilitation interventions aimed at improving balance and walking performance, fatigue management, and specific pain relief therapy should be considered to ameliorate participation in social life and HR-QoL in anti-MAG neuropathy patients.

KW - Balance

KW - Chronic inflammatory polyneuropathy

KW - MGUS

KW - Pain

KW - Rehabilitation

KW - Walking ability

U2 - 10.1007/s00415-018-9081-7

DO - 10.1007/s00415-018-9081-7

M3 - Article

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -